膀胱内电动力导入A型肉毒毒素(Dysport)治疗脊髓脊膜膨出患儿
本文介绍电动力药物导入(EMDA)技术在脊髓脊膜膨出伴神经源性逼尿肌过度活动所致尿失禁患儿中的应用。通过视频展示无需全麻、无需膀胱镜的门诊操作技术,使用10 IU/kg Dysport以特定电流参数导入膀胱。结果显示1年随访时75%患儿尿失禁改善,平均最大膀胱测压容量从基线148±62 mL显著增加至治疗后1年239±73 mL。
要点
- EMDA是膀胱内灌注治疗药物的微创方法,无需全麻。
- 本中心首次在脊髓脊膜膨出尿失禁患儿中实施BoNTA/EMDA。
- 1年随访时75%患儿尿失禁改善,最大膀胱测压容量显著增加。
核心结论
- 该技术是一种可行、安全、可重复、经济、持久且无痛的门诊方法,长期有效,无需麻醉或膀胱镜操作。
研究设计与样本
- 本视频展示在脊髓脊膜膨出伴神经源性逼尿肌过度活动所致尿失禁患儿中实施A型肉毒毒素电动力药物导入(BoNTA/EMDA)的可行性。
主要发现
- 本中心首次在脊髓脊膜膨出尿失禁患者中实施BoNTA/EMDA。
- 根据我们既往报告,1年随访时75%的患者在连续两次清洁间歇导尿之间尿失禁改善。
- 平均最大膀胱测压容量从基线148±62 mL显著增加至治疗后1年239±73 mL。
关键数值与推荐
- BoNTA(Dysport)剂量为10 IU/kg,加入膀胱内溶液。
- 脉冲电流发生器参数:频率2,800 Hz,间隔50 µs,振幅10-20 mA,持续20分钟。
- 使用10-Fr导管电极,2%利多卡因凝胶行局部经尿道麻醉,导管气囊注入2 cc生理盐水。
临床怎么用
- 该技术可在门诊进行,无需全身麻醉或膀胱镜操作。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Electromotive drug administration (EMDA) presents a minimally invasive method of intravesical instillation of therapeutic agents without the need for general anesthesia.1 It employs a combination of iontophoresis, electrophoresis, and electroporation to deliver drugs into deep tissue layers using an electrical current created between 2 electrodes.2 This video shows feasibility of botulinum toxin type A (BoNTA) EMDA in myelomeningocele children with urinary incontinence secondary to neuropathic detrusor overactivity. METHODS: In this technique (Video 1), catheterization was performed with a 10-Fr (CE-DAS, UROGENICS/Ag 9900 (pediatric), Mirandola, Italy) catheter electrode, after providing a local transurethral anesthesia with 2% lidocaine gel. The cuff of the catheter was filled by 2 cc saline solution. The bladder was then drained and irrigated with 0.9% saline solution until the catheter outflow became clear. The bladder was subsequently filled with sterile water to its maximal capacity. BoNTA (Dysport) at a dose of 10 IU/kg was added to the intravesical solution. Negative electrode as 2 dispersive electrodes was placed on the abdomen. Positive electrode was connected to the intravesical catheter. A pulsed current generator (Physionizer 30, Physion srl, Mirandola, Italy), delivered a current with frequency of 2,800 Hz, interval of 50 µs and amplitude of 10-20 mA for 20 minutes. At the end of the procedure, the bladder was emptied. RESULTS: For the first time, BoNTA/EMDA was performed on myelomeningocele patients with urinary incontinence in our center.3 According to our prior reports, urinary incontinence improved in 75% of the patients between 2 consecutive clean intermittent catheterizations at 1-year follow-up.4 Mean maximal cystometric capacity significantly increased from 148 ± 62 mL at baseline to 239 ± 73 mL 1 year after the treatment.4 CONCLUSION: This technique is a feasible, safe, reproducible, cost effective, long lasting, and pain free method, on an outpatient basis with long-term duration of effects and without anesthesia or cystoscopy procedure.
引用
- Sharifi-Rad L, Ladi-Seyedian SS, Nabavizadeh B, et al. Intravesical Electromotive Botulinum Toxin Type A (Dysport) Administration in Children With Myelomeningocele. Urology. 2019. PMID: 31299327. doi:10.1016/j.urology.2019.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。